|
Synonyms: Beovu® | brolucizumab-dbll | ESBA-1008 | ESBA1008 | RTH258
brolucizumab is an approved drug (FDA (2019), EMA (2020))
Compound class:
Antibody
Comment: Brolucizumab is a single-chain variable fragment (scFv) anti-VEGF antibody targeting vascular endothelial growth factor A (VEGFA). This immunobinder was derived from a humanised anti-VEGFA rabbit monoclonal [2].
Peptide sequence and secondary structural information are available from brolucizumab's IMGT/mAb-DB record. Peptide sequence alignment analysis of patented peptide sequences using the heavy chain variable region of brolucizumab identifies a 100% match with SEQ ID NO: 164 in patent US8349322 B2 [1]. Following regulatory approval brolucizumab took its place as a wet age-related macular degeneration therapy alongside aflibercept (Eylea®) and ranibizumab (Lucentis®), which were previously the main drugs used for this indication. However, with patent protection for both of these older dugs due to expire in the next 2-5 years [4], brolucizumab will likely face competition from aflibercept and ranibizumab biosimilars. |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2019), EMA (2020)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10053 | brolucizumab |
| Synonyms |
| Beovu® | brolucizumab-dbll | ESBA-1008 | ESBA1008 | RTH258 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 536 |
Reactome Drug
|
R-ALL-9679482 |
|
Reactome Reaction
|
R-HSA-9679477 |
| Other databases | |
| GtoPdb PubChem SID | 252827371 |
| Search PubMed clinical trials | brolucizumab |
| Search PubMed titles | brolucizumab |
| Search PubMed titles/abstracts | brolucizumab |
